Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 33 min ago
Peer-reviewedCC BYCell death & disease

Human cortico-vascular assembloids reveal a CELF2-AHNAK-dependent switch from neuronal to endothelial tropism in glioblastoma cells.

2 more authors
7 affiliations
  1. 1Université Côte D'Azur, CNRS, Inserm, iBV, Nice, France.
  2. 2DRCI, CHU de Nice, Nice, France.
  3. 3Sorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 7 Quai Saint-Bernard, Paris, France.
  4. 4Service de Neurochirurgie, Hôpital Pasteur, CHU de Nice, Nice, France.
  5. 5Service d'Anatomopathologie, Hôpital Pasteur, CHU de Nice, Nice, France.
  6. 6Université Côte D'Azur, CNRS, Inserm, iBV, Nice, France. [email protected].
  7. 7Université Côte D'Azur, CNRS, Inserm, iBV, Nice, France. [email protected].

Abstract

Glioblastoma (GBM) remains one of the most aggressive human cancers, driven by cellular plasticity and dynamic interactions with the neurovascular niche. Yet, further refinement of existing preclinical models is needed to improve the reproduction of the human brain-vascular interface and facilitate the study of tumor-host crosstalk and invasion. To address this limitation, we developed a human induced pluripotent stem cell (hiPSC)-derived cortico-endothelial (CO + EO) assembloid model by fusing cortical and endothelial organoids. These assembloids spontaneously form branched vascular networks enriched in tight junction proteins (CLDN5, OCLN, ZO-1), thereby recapitulating key BBB-like features and providing a physiologically relevant human platform to investigate GBM-neurovascular interactions. Using this system, we uncovered a previously unrecognized CELF2-dependent glioma stem cell (GSC) tropism. CELF2-expressing GSCs preferentially infiltrate neural regions, where they induce neuronal apoptosis and disrupt endothelial tight junction structure, supporting an aggressive phenotype. In contrast, CELF2-deficient GSCs lose neurotropism, acquire mesenchymal features, and are redirected toward vascular compartments. This endothelial affinity depends on the scaffold protein AHNAK, strongly expressed at the plasma membrane of CELF2-deficient cells and enriched at tumor-endothelial interfaces. AHNAK knockdown partially abolishes endothelial infiltration, demonstrating its role in GBM vascular tropism. Moreover, analysis of patient GBM specimens confirmed that CELF2-positive tumor cells are enriched in poorly vascularized, mitotically active regions and are largely excluded from vessel-rich zones, closely resembling the behavior observed in assembloids. Transcriptomic profiling further revealed that CELF2 promotes a neuronal progenitor-like program while repressing mesenchymal and vascular-associated gene signatures, thereby shaping tumor identity, invasive behavior, and tissue preference. Collectively, this study establishes CO + EO assembloids as an original human model of GBM plasticity at the neurovascular interface. We identify CELF2 as a master regulator of GSC tropism and AHNAK as a mediator of vascular affinity, revealing a molecular axis that governs GBM invasion and providing potential avenues for future therapeutic intervention. Schematic representation of CO + EO assembloids comprising an endothelial (yellow) and a cortical (red) domain. On the left, control CELF2-expressing GBM cells preferentially infiltrate the neuronal compartment, where they trigger neuronal apoptosis and disrupt the expression of the tight junction protein CLDN5 upon contact with endothelial cells. On the right, CELF2-deprived GBM cells exhibit reduced neural invasion and increased tropism for endothelial cells, consistent with a mesenchymal signature shift partially driven by elevated AHNAK expression. These cells exert limited impact on neuronal viability and BBB integrity, and display partial loss of GSC identity, as indicated by reduced OLIG2 expression. The CO + EO assembloid model thus recapitulates key features of cortico-endothelial human tissue heterogeneity and provides a reliable platform to dissect the molecular mechanisms underlying GSC tropism and their tissue-specific interactions.

Related

  1. Blood-brain barrier and blood-tumoral barrier formation in glioblastoma: endothelial cells and glioblastoma stem cells at the immune-brain crossroad
    Maria Rosito, Ruth Lyck, Britta Engelhardt +1
    Fluids and Barriers of the CNSPeer-reviewedCC BYFull textHuman geneticsDOAJ
  2. Vascular endothelial growth factor mRNA in eutopic and ectopic endometrium
    Philip Kressin, Eva-Maria Wolber, Harald Wodrich +4
    Fertility and SterilityPeer-reviewedLicence not statedFull text31 citedObstetrics, gynaecology & paediatricsHAL
  3. Serum Tumstatin and Vascular Endothelial Growth Factor Levels in Patients with Rosacea: A Cross-Sectional Case–Control Study
    Mahir Dığış, Emel Güneş, Kısmet Kaya +2
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Intravitreal Anti-vascular Endothelial Growth Factor Injection Practices Among Indonesian Vitreoretinal Specialists: Findings From a 2021 National Survey
    Andrea Silitonga, Hanna Tabita Hasianna Silitonga, Rova Virgana +4
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Vascular Phenotyping Across the CKM Syndrome: Arterial Stiffness and Endothelial Function Testing, Prognostic Value and Clinical Implementation
    Cezara-Andreea Gerdanovics, Teodora-Gabriela Alexescu, Cezar Login +13
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{bertacchi2026human,
  title = {{Human cortico-vascular assembloids reveal a CELF2-AHNAK-dependent switch from neuronal to endothelial tropism in glioblastoma cells.}},
  author = {Michele Bertacchi and Annie Ladoux and Alexa Saliou and Gwendoline Maharaux and Clément Peux and Laurent Turchi and Béatrice Polo and Hervé Chneiweiss and Elias El-Habr and Marie Pierre Junier and Fabien Almairac and Fanny Burel-Vandenbos and Michèle Studer and Thierry Virolle},
  journal = {Cell death \& disease},
  year = {2026},
  month = aug,
  doi = {10.1038/s41419-026-09169-z},
  url = {https://europepmc.org/article/MED/42971976},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Human cortico-vascular assembloids reveal a CELF2-AHNAK-dependent switch from neuronal to endothelial tropism in glioblastoma cells.
AU  - Michele Bertacchi
AU  - Annie Ladoux
AU  - Alexa Saliou
AU  - Gwendoline Maharaux
AU  - Clément Peux
AU  - Laurent Turchi
AU  - Béatrice Polo
AU  - Hervé Chneiweiss
AU  - Elias El-Habr
AU  - Marie Pierre Junier
AU  - Fabien Almairac
AU  - Fanny Burel-Vandenbos
AU  - Michèle Studer
AU  - Thierry Virolle
PY  - 2026
DA  - 2026/08/05
JO  - Cell death & disease
DO  - 10.1038/s41419-026-09169-z
UR  - https://europepmc.org/article/MED/42971976
AB  - Glioblastoma (GBM) remains one of the most aggressive human cancers, driven by cellular plasticity and dynamic interactions with the neurovascular niche. Yet, further refinement of existing preclinical models is needed to improve the reproduction of the human brain-vascular interface and facilitate the study of tumor-host crosstalk and invasion. To address this limitation, we developed a human induced pluripotent stem cell (hiPSC)-derived cortico-endothelial (CO + EO) assembloid model by fusing cortical and endothelial organoids. These assembloids spontaneously form branched vascular networks enriched in tight junction proteins (CLDN5, OCLN, ZO-1), thereby recapitulating key BBB-like features and providing a physiologically relevant human platform to investigate GBM-neurovascular interactions. Using this system, we uncovered a previously unrecognized CELF2-dependent glioma stem cell (GSC) tropism. CELF2-expressing GSCs preferentially infiltrate neural regions, where they induce neuronal apoptosis and disrupt endothelial tight junction structure, supporting an aggressive phenotype. In contrast, CELF2-deficient GSCs lose neurotropism, acquire mesenchymal features, and are redirected toward vascular compartments. This endothelial affinity depends on the scaffold protein AHNAK, strongly expressed at the plasma membrane of CELF2-deficient cells and enriched at tumor-endothelial interfaces. AHNAK knockdown partially abolishes endothelial infiltration, demonstrating its role in GBM vascular tropism. Moreover, analysis of patient GBM specimens confirmed that CELF2-positive tumor cells are enriched in poorly vascularized, mitotically active regions and are largely excluded from vessel-rich zones, closely resembling the behavior observed in assembloids. Transcriptomic profiling further revealed that CELF2 promotes a neuronal progenitor-like program while repressing mesenchymal and vascular-associated gene signatures, thereby shaping tumor identity, invasive behavior, and tissue preference. Collectively, this study establishes CO + EO assembloids as an original human model of GBM plasticity at the neurovascular interface. We identify CELF2 as a master regulator of GSC tropism and AHNAK as a mediator of vascular affinity, revealing a molecular axis that governs GBM invasion and providing potential avenues for future therapeutic intervention. Schematic representation of CO + EO assembloids comprising an endothelial (yellow) and a cortical (red) domain. On the left, control CELF2-expressing GBM cells preferentially infiltrate the neuronal compartment, where they trigger neuronal apoptosis and disrupt the expression of the tight junction protein CLDN5 upon contact with endothelial cells. On the right, CELF2-deprived GBM cells exhibit reduced neural invasion and increased tropism for endothelial cells, consistent with a mesenchymal signature shift partially driven by elevated AHNAK expression. These cells exert limited impact on neuronal viability and BBB integrity, and display partial loss of GSC identity, as indicated by reduced OLIG2 expression. The CO + EO assembloid model thus recapitulates key features of cortico-endothelial human tissue heterogeneity and provides a reliable platform to dissect the molecular mechanisms underlying GSC tropism and their tissue-specific interactions.
SN  - 2041-4889
ER  -